Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AMG 794 |
Synonyms | |
Therapy Description |
AMG 794 is a bispecific T-cell engager that targets CLDN6 and CD3, potentially leading to enhanced antitumor immune response and killing of tumor cells expressing CLDN6 (Cancer Res (2022) 82 (12_Supplement): 5202). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AMG 794 | AMG-794|AMG794 | CD3 Antibody 99 CLDN6 Antibody 8 | AMG 794 is a bispecific T-cell engager that targets CLDN6 and CD3, potentially leading to enhanced antitumor immune response and killing of tumor cells expressing CLDN6 (Cancer Res (2022) 82 (12_Supplement): 5202). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05317078 | Phase I | AMG 794 | A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications | Terminated | USA | CHE | AUS | 0 |